Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Clinical Advances in Myocardial Infarction
share announcement

Clinical Advances in Myocardial Infarction

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 10 October 2024 | Viewed by 6263

Special Issue Editors

Dr. Luca Donazzan

E-Mail Website
Guest Editor
Department of Cardiology, San Maurizio Hospital, Bolzano, Italy
Interests: acute coronary syndromes; percutaneous coronary intervention; myocardial revascularization; coronary physiology; elderly population
Dr. Simone Biscaglia

E-Mail Website
Guest Editor
Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy
Interests: acute coronary syndromes; percutaneous coronary intervention; intracoronary physiology; elderly population
Dr. Giulia Masiero

E-Mail Website
Guest Editor
Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padova, Italy
Interests: acute coronary syndromes; percutaneous coronary intervention; bioresorbable vascular scaffold; transcatheter heart therapies; transcatheter aortic valve implantation; transcatheter mitral valve repair; transcatheter tricuspid valve repair

Special Issue Information

Dear Colleagues,

The prognostic relevance of the rapid and effective treatment of myocardial infarction (MI) is well established. Since the development of primary percutaneous intervention (pPCI), the mortality and morbidity of MI has dramatically reduced. Both procedural aspects of pPCI as well as periprocedural pharmacotherapy has contributed to further improvements in care. Nowadays, the use of an invasive approach is also aimed at frail and elderly patients with multiple comorbidities (e.g., anaemia, chronic kidney disease, diabetes mellitus) affected by acute coronary syndromes (ACSs). Technological advances have also enabled the acute treatment of calcified lesions, complex bifurcations, and multivessel coronary artery disease. Moreover, the use of intracoronary imaging, physiology, and left ventricular assistance has improved the safety and efficacy of PCI procedures.

Notwithstanding, many issues in the treatment of ACS deserve further investigation, from risk prediction modelling, medical treatment strategies, timing of angiography, and revascularization strategies (especially in the evolving scenario of acute MI with no obstructive coronary arteries (MINOCA)) to long-term management.

This Special Issue focuses on the cutting-edge treatment strategies, devices, and tools used for acute coronary syndromes; we invite the submission of original clinical studies, reviews, and state-of-the-art manuscripts which revolve around this topic.

Dr. Luca Donazzan
Dr. Simone Biscaglia
Dr. Giulia Masiero
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute myocardial infarction
  • elderly
  • percutaneous coronary intervention
  • complex coronary lesions
  • intravascular imaging
  • multivessel disease
  • coronary physiology
  • dual antiplatelet therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

17 pages, 1876 KiB  
Review
Antiplatelet Therapy and Anticoagulation before, during, and after Acute Coronary Syndrome
by Christoph C. Kaufmann, Marie Muthspiel, Laura Lunzer, Edita Pogran, David Zweiker, Achim Leo Burger, Johann Wojta and Kurt Huber
J. Clin. Med. 2024, 13(8), 2313; https://doi.org/10.3390/jcm13082313 - 17 Apr 2024
Viewed by 2086
Abstract
Acute coronary syndrome (ACS) remains a major challenge in clinical practice, requiring rapid and effective antithrombotic treatment to mitigate adverse ischemic events while minimizing the risk of bleeding. In recent years, results from several clinical trials addressing this issue through various approaches have [...] Read more.
Acute coronary syndrome (ACS) remains a major challenge in clinical practice, requiring rapid and effective antithrombotic treatment to mitigate adverse ischemic events while minimizing the risk of bleeding. In recent years, results from several clinical trials addressing this issue through various approaches have substantially improved the treatment landscape for patients presenting with ACS. The emergence of new, potent P2Y12 inhibitors has significantly enhanced thrombotic risk reduction and different strategies for de-escalating and shortening dual antiplatelet therapy (DAPT) have demonstrated promising outcomes in reducing bleeding rates. Furthermore, data from ongoing trials focusing on novel therapeutic agents and investigating alternative treatment strategies to optimize outcomes for ACS patients are expected in the next few years. In this review, we summarize the current knowledge and emphasize the critical role of individualized treatment approaches tailored to patient-specific risk factors and individual clinical scenarios. Full article
(This article belongs to the Special Issue Clinical Advances in Myocardial Infarction)
►▼ Show Figures

Figure 1

16 pages, 1005 KiB  
Review
Lipid-Lowering Therapy after Acute Coronary Syndrome
by Edita Pogran, Achim Leo Burger, David Zweiker, Christoph Clemens Kaufmann, Marie Muthspiel, Gersina Rega-Kaun, Alfa Wenkstetten-Holub, Johann Wojta, Heinz Drexel and Kurt Huber
J. Clin. Med. 2024, 13(7), 2043; https://doi.org/10.3390/jcm13072043 - 1 Apr 2024
Viewed by 3851
Abstract
Achieving guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets remains a significant challenge in clinical practice. This review assesses the barriers to reaching LDL-C goals and explores the potential solutions to these issues. When aiming for the recommended LDL-C goal, strategies like “lower is better” [...] Read more.
Achieving guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets remains a significant challenge in clinical practice. This review assesses the barriers to reaching LDL-C goals and explores the potential solutions to these issues. When aiming for the recommended LDL-C goal, strategies like “lower is better” and “strike early and strong” should be used. The evidence supports the safety and efficacy of intensive lipid-lowering therapy post-acute coronary syndrome (ACS), leading to improved long-term cardiovascular health and atherosclerotic plaque stabilization. Despite the availability of effective lipid-lowering therapies, such as high-intensity statins, ezetimibe, the combination of both, bempedoic acid, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a substantial proportion of patients do not meet their LDL-C targets. Contributing factors include systemic healthcare barriers, healthcare provider inertia, patient non-adherence, and statin intolerance. Statin intolerance, often rather statin reluctance, is a notable obstacle due to perceived or expected side effects, which can lead to discontinuation of therapy. In conclusion, while there are obstacles to achieving optimal LDL-C levels post-ACS, these can be overcome with a combination of patient-centric approaches, clinical vigilance, and the judicious use of available therapies. The safety and necessity of reaching lower LDL-C goals to improve outcomes in patients post-ACS are well-supported by current evidence. Full article
(This article belongs to the Special Issue Clinical Advances in Myocardial Infarction)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop